Estimated time to complete activity: 1.0 hour
Date of initial release: August 16, 2013
Valid for CME/CPE/CE credit through: August 16, 2014
This program was developed for health system pharmacists and oncology pharmacists involved in the management of chemotherapy-induced nausea and vomiting (CINV).
Upon completion of this activity, the participant will be able to:
- Discuss recent advances and emerging therapies in the treatment of
patients with CINV
- Evaluate key recommendations from updated clinical practice guidelines
for the management of CINV, including those established by ASCO,
NCCN, MASCC, and ONS
- Formulate effective treatment strategies for improving outcomes in
patients with CINV
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute Inc for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
James J. Natale, PharmD, BCOP, is on the Speakers’ bureau for Eisai and Merck. He does intend to discuss either non-FDA-approved or investigational
use for the following products/devices: NEPA and rolapitant.
Joanna Schwartz, PharmD, BCOP, has nothing to disclose. She does intend to discuss either non-FDA-approved or investigational use for the following products/
devices: aprepitant, published studies for challenging cases in CINV.
The associates of Medical Learning Institute Inc, the accredited provider for this activity, and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CPE activity for any amount during the past 12 months.
Planners' and Managers' Disclosures
Dana Delibovi, Medical Writer, has nothing to disclose. She does intend to discuss either non–FDA-approved or investigational use for the following products/devices: AFP530; NEPA, netupitant.
Teresa Haile, RPh, MBA, has nothing to disclose.
Joanna Schwartz, PharmD, BCOP
Department of Pharmacy Practice
Albany College of Pharmacy
and Health Sciences
James J. Natale, PharmD, BCOP
Manager, Outpatient Oncology
a partner with University of
Pittsburgh Cancer Institute
This activity is jointly sponsered by Medical Learning Institute Inc and Center of Excellence Media, LLC.
|Commercial Support Acknowledgement
This activity is supported by an educational grant from Eisai, Inc.
|Instructions for Credit
There is no fee for this activity. To receive credit after reading this CPE activity in its entirety, participants must complete the pretest, posttest, and evaluation. The pretest, posttest, and evaluation can be completed online at www.mlicme.org/P13020.html. Upon completion of the evaluation and scoring 70% or better on the posttest, you will immediately receive your certificate online. If you do not achieve a score of 70% or better on the posttest, you will be asked to take it again. Please retain a copy of the Certificate for your records.
For questions regarding the accreditation of this activity, please contact Medical Learning Institute Inc at 609-333-1693 or email@example.com.
For pharmacists, Medical Learning Institute Inc will report your
participation in this educational activity to the NABP only if you
provide your NABP e-Profile number and date of birth. For more
information regarding this process or to get your NABP e-Profile
number, go to www.mycpemonitor.net.
|Registered Pharmacy Designation
The Medical Learning Institute Inc is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this knowledge-based activity provides for 1.0 contact hour (0.1 CEU) of continuing pharmacy education credit. The Universal Activity Number for this actviity is 0468-9999-13-010-H01-P.
The information provided in this CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.